189955-77-9

Basic information

• Product Name: 2-(2.4-Difluorophenoxy)acetic acid 2-methyl-1-(4-(methylsulfonyl) phenyl)propan-1-one-2-yl ester
• Synonyms: 2-(2.4-Difluorophenoxy)acetic acid 2-methyl-1-(4-(methylsulfonyl) phenyl)propan-1-one-2-yl ester
• CAS NO: 189955-77-9
• Molecular Weight: 412.411
• Mol File: 189955-77-9.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 2-(2.4-Difluorophenoxy)acetic acid 2-methyl-1-(4-(methylsulfonyl) phenyl)propan-1-one-2-yl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(2.4-Difluorophenoxy)acetic acid 2-methyl-1-(4-(methylsulfonyl) phenyl)propan-1-one-2-yl ester(189955-77-9)
• EPA Substance Registry System: 2-(2.4-Difluorophenoxy)acetic acid 2-methyl-1-(4-(methylsulfonyl) phenyl)propan-1-one-2-yl ester(189955-77-9)

Safety Data

• Hazardous Substances Data: 189955-77-9(Hazardous Substances Data)

Upstream product

• 53207-58-2 2-methyl-1-(4-(methylthio)phenyl)-propan-1-one 
• 100-68-5 methyl-phenyl-thioether 
• 399-44-0 2-(2,4-difluorophenoxy)acetic acid 
• 180048-73-1 2-hydroxy-2-methyl-1-(4-(methylsulfonyl)-phenyl)propan-1-one 
• 71867-98-6 2-hydroxy-2-methyl-1-(4-(methylthio)phenyl)-propan-1-one 

Relevant articles and documents

A new structural variation on the methanesulfonylphenyl class of selective cyclooxygenase-2 inhibitors

By inserting an oxygen link between the 3-fluorophenyl and the lactone ring of 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methanesulfonylphenyl)-2(5H)-furanone 1 (DFU), analogs with enhanced in vitro COX-2 inhibitory potency as well as in vivo potency in models of inflammation were obtained.

ALKYLATED STYRENES AS PRODRUGS TO COX-2 INHIBITORS

The invention encompasses the novel compound of formula (I) useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of formula (I).

Alkylated styrenes as prodrugs to COX-2 inhibitors

The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.